Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata netindia123.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from netindia123.com Daily Mail and Mail on Sunday newspapers.
MUMBAI (Maharashtra) [India]/ Lexington [Kentucky], Jan 20: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO ) (Bloomberg: SUNP IN) (NSE: SUNPHARMA) (BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) (“Concert”) today announced that they have executed a definitive agreement under which Sun Pharma will acquire all outstanding shares of Concert through a tender offer for an upfront payment of USD 8.00 per share of common stock in cash, or USD 576 million […]
Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease
Leverages Sun .
Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun.
Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun Pharma's Global Infrastructure